Shane Todd Marshall Eleniak - 12 Feb 2026 Form 4 Insider Report for CALIX, INC ((CALX))

Reporting relationship: Chief Product Officer
Issuer ticker: (CALX)
Reported as of: 12 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Feb 2026, 16:04:56 UTC
Prior SEC filing: 12 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak

Key filing fact

Shane Todd Marshall Eleniak filed Form 4 for CALIX, INC ((CALX)) on 17 Feb 2026.

Key facts

This page summarizes Shane Todd Marshall Eleniak's Form 4 filing for CALIX, INC ((CALX)).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Feb 2026, 16:04.

Change

Previous filing in this sequence was filed on 12 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001886143 Primary reporting owner

Eleniak Shane Todd Marshall

Relationship: Chief Product Officer
Address: C/O CALIX, INC., 3155 OLSEN DRIVE, SUITE 450, SAN JOSE
Signature: /s/ Tom Gemetti as Attorney-in-fact for Shane Eleniak
Signature date: 17 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

(CALX) transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +195,000
Change %
Price: $0.000000
Shares after: 195,000
Date: 12 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 195,000
Exercise price: $39.68
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On January 31, 2025, the reporting person was granted a performance-based option to purchase 195,000 shares of common stock. On February 12, 2026, the Compensation Committee determined that the performance criteria governing 100% of the grant had been achieved. The option vests: (i) as to 25% of the shares of common stock subject to the stock option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.